PT Kalbe Farma Tbk. Stock price

Equities

KLBF

ID1000125107

Pharmaceuticals

End-of-day quote INDONESIA S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
1,475 IDR +1.03% Intraday chart for PT Kalbe Farma Tbk. -0.34% -8.39%
Sales 2023 * 30,922B 1.95B Sales 2024 * 33,014B 2.08B Capitalization 68,227B 4.3B
Net income 2023 * 2,828B 178M Net income 2024 * 3,460B 218M EV / Sales 2023 * 2.07 x
Net cash position 2023 * 4,191B 264M Net cash position 2024 * 5,518B 348M EV / Sales 2024 * 1.9 x
P/E ratio 2023 *
24 x
P/E ratio 2024 *
19.8 x
Employees 13,134
Yield 2023 *
2.32%
Yield 2024 *
2.14%
Free-Float 40.45%
More Fundamentals * Assessed data
Dynamic Chart
Nomura Adjusts Kalbe Farma’s Price Target to IDR1,850 From IDR2,500, Keeps at Buy MT
PT Kalbe Farma Tbk. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
PT Kalbe Farma Tbk. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Nomura Adjusts Kalbe Farma’s Price Target to IDR2,500 From IDR2,250, Keeps at Buy MT
Progen Co. Ltd. announced that it has received IDR 155.72 billion in funding from PT Kalbe Farma Tbk. CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
PT Kalbe Farma Tbk. completed the acquisition of a 80% stake in PT Aventis Pharma from Hoechst GmbH and Sanofi-Aventis Participations S.A.S. CI
Nomura Adjusts Kalbe Farma's Price Target to 2,250 Rupiahs From 1,905 Rupiahs, Keeps at Buy MT
PT Kalbe Farma Tbk. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
PT Kalbe Farma Tbk. entered into agreement to acquire 80% stake in PT Aventis Pharma from Hoechst GmbH and Sanofi-Aventis Participations S.A.S. CI
PT Kalbe Farma Tbk.'s Equity Buyback announced on February 10, 2022, has expired. CI
PT Kalbe Farma Tbk. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
More news
1 day-2.99%
1 week-1.35%
Current month-2.01%
3 months-9.88%
6 months-16.81%
Current year-9.32%
More quotes
1 week
1 460.00
Extreme 1460
1 535.00
1 month
1 405.00
Extreme 1405
1 535.00
Current year
1 405.00
Extreme 1405
1 620.00
1 year
1 405.00
Extreme 1405
2 220.00
3 years
1 240.00
Extreme 1240
2 360.00
5 years
830.00
Extreme 830
2 360.00
10 years
830.00
Extreme 830
2 360.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 96-12-31
Director of Finance/CFO - 17-01-31
Chairman 61 97-02-28
Members of the board TitleAgeSince
Director/Board Member 59 99-12-31
Director/Board Member 51 07-12-31
Chairman 61 97-02-28
More insiders
Date Price Change Volume
24-03-27 1,475 +1.03% 30 183 200
24-03-27 1,460 -2.99% 20,490,100
24-03-26 1,505 -0.99% 32,682,200
24-03-25 1,520 +2.36% 22,175,400
24-03-22 1,485 +1.71% 23,371,300

End-of-day quote INDONESIA S.E., March 26, 2024

More quotes
PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
1,460 IDR
Average target price
1,788 IDR
Spread / Average Target
+22.47%
Consensus
  1. Stock
  2. Equities
  3. Stock PT Kalbe Farma Tbk. - INDONESIA S.E.